Enable Accessibility Enable Accessibility

Our Medicines

To contact Medical Information about our products or report an adverse event, click here.

 

Focusing on the health of Canadians

Takeda’s top priority is the health of Canadians. Their well-being is central to our work and drives our commitment to deliver a diverse portfolio of innovative treatments.


Current important medicines available to Canadians from Takeda Canada include:

 

For legacy Shire product information, click here:
https://www.takeda.com/en-ca/what-we-do/our-medicines/shire-products

PRODUCTS

 

ADDERALL XR®

mixed salts amphetamine

Product Monograph

ADYNOVATE

Antihemophilic Factor (Recombinant), PEGylated

Product Monograph

ALUNBRIG®

brigatinib

Product Monograph

CINRYZE®

C1 inhibitor [human]

Product Monograph

CUVITRU®

Normal Immunoglobulin (Human)

Product Monograph

DEXILANT®

dexlansoprazole

Product Monograph

ELAPRASE®

idursulfase for injection

Product Monograph

ENTYVIO®

vedolizumab

Product Monograph

FEIBA® NF

Anti-Inhibitor Coagulant Complex

Product Monograph

FIRAZYR®

icatibant injection

Product Monograph

FOSRENOL®

lanthanum carbonate hydrate

Product Monograph

GAMMAGARD LIQUID®

Immunoglobulin Intravenous (Human)

Product Monograph

IMMUNINE® VH

Factor IX Concentrate (Human)

Product Monograph

INTUNIV XR®

guanfacine hydrochloride

Product Monograph

KAZANO®

alogliptin (as alogliptin benzoate) and metformin hydrochloride

Product Monograph

MEZAVANT®

mesalamine

Product Monograph

NESINA®

alogliptin (as alogliptin benzoate)

Product Monograph

NINLARO®

ixazomib (as ixazomib citrate)

Product Monograph

OBIZUR®

Antihemophilic Factor (Recombinant), Porcine Sequence

Product Monograph

ONDISSOLVE® ODF

ondansetron

Product Monograph

PANTOLOC®

pantoprazole sodium

Product Monograph

REPLAGAL®

agalsidase alfa for injection

Product Monograph

REVESTIVE®

Teduglutide for injection

Product Monograph

RIXUBIS®

Recombinant Coagulation Factor IX (rFIX), Nonacog gamma for Injection

Product Monograph

TAKHZYRO®

lanadelumab injection

Product Monograph

TECTA®

pantoprazole magnesium

Product Monograph

ULORIC®

febuxostat

Product Monograph 

Health Product Risk Communication
(November 2019)

VONVENDI®

Lyophilized Powder for Solution

Product Monograph

VPRIV®

velaglucerase alfa

Product Monograph

VYVANSE®

lisdexamfetamine dimesylate

Product Monograph
 
ADDERALL XR® and ADDERALL® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc.
ALUNBRIG® and the ALUNBRIG Logo® are registered trademarks of ARIAD Pharmaceuticals, Inc.
CINRYZE® and the CINRYZE Logo are registered trademarks of ViroPharma Biologics LLC, a Takeda company.
CUVITRU® is a registered trademark of Baxalta Incorporated.
DEXILANT® is a trademark of Takeda Pharmaceuticals U.S.A., Inc and used under licence by Takeda Canada Inc.
ELAPRASE® and the ELAPRASE Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.
ENTYVIO® is a registered trademark of Millennium Pharmaceuticals, Inc. and used under licence by Takeda Canada Inc.
FEIBA® is a registered trademark of Baxalta Incorporated.
FIRAZYR® and the FIRAZYR Logo are registered trademarks of Shire Orphan Therapies GmbH.
FOSRENOL® and the FOSRENOL Logo are registered trademarks of Shire International Licensing BV, a Takeda company.
GAMMAGARD® and GAMMAGARD LIQUID® are registered trademarks of Baxalta Incorporated.
IMMUNINE® is a registered trademark of Baxalta Incorporated.
INTUNIV XR® is a registered trademark of Takeda Pharmaceuticals U.S.A., Inc.
KAZANO® is a trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Canada Inc.
MEZAVANT® and the MEZAVANT Logo® are registered trademarks of Nogra Pharma Limited, used under license.
NESINA® is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Canada Inc.
NINLARO® is a registered trademark of Millennium Pharmaceuticals, Inc. 
ONDISSOLVE® is a registered trademark of Takeda GmbH. 
PANTOLOC® and TECTA® are registered trademarks of Takeda GmbH. Used under licence.
REPLAGAL® and the REPLAGAL Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.
REVESTIVE® is a registered trademark of Shire-NPS Pharmaceuticals, Inc., a Takeda company.
RIXUBIS® and BAXJECT® II are registered trademarks of Baxalta Incorporated.
TAKHZYRO® is a registered trademark of Dyax Corp.
ULORIC® is a registered trademark of Teijin Limited and used under licence by Takeda Canada Inc.
VONVENDI® is a registered trademark of Baxalta Incorporated.
VPRIV® and the VPRIV Logo® are registered trademarks of Shire Human Genetic Therapies, Inc.